| Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours S Severi, O Nanni, L Bodei, M Sansovini, A Ianniello, S Nicoletti, E Scarpi, ... European journal of nuclear medicine and molecular imaging 40, 881-888, 2013 | 156 | 2013 |
| 177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study G Paganelli, M Sansovini, A Ambrosetti, S Severi, M Monti, E Scarpi, ... European journal of nuclear medicine and molecular imaging 41, 1845-1851, 2014 | 123 | 2014 |
| Formation of the Galactic Halo... Inside and Out R Gratton, E Carretta, F Matteucci, C Sneden, HL Morrison, A Sarajedini ASP Conf. Ser. 92, 307, 1996 | 110 | 1996 |
| Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone U De Giorgi, P Caroli, SL Burgio, C Menna, V Conteduca, E Bianchi, ... Oncotarget 5 (23), 12448, 2014 | 109 | 2014 |
| 18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide U De Giorgi, P Caroli, E Scarpi, V Conteduca, SL Burgio, C Menna, ... European journal of nuclear medicine and molecular imaging 42, 1276-1283, 2015 | 101 | 2015 |
| 68Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients P Caroli, I Sandler, F Matteucci, U De Giorgi, L Uccelli, M Celli, F Foca, ... European journal of nuclear medicine and molecular imaging 45, 2035-2044, 2018 | 99 | 2018 |
| Investigation of receptor radionuclide therapy with 177Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index S Nicolini, S Severi, A Ianniello, M Sansovini, A Ambrosetti, ... European journal of nuclear medicine and molecular imaging 45, 923-930, 2018 | 88 | 2018 |
| Dosimetry and safety of 177Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer … G Paganelli, A Sarnelli, S Severi, M Sansovini, ML Belli, M Monti, F Foca, ... European Journal of Nuclear Medicine and Molecular Imaging 47, 3008-3017, 2020 | 56 | 2020 |
| Biomarkers and molecular imaging as predictors of response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer C Molinari, F Matteucci, P Caroli, A Passardi Clinical colorectal cancer 14 (4), 227-238, 2015 | 43 | 2015 |
| Tumor targeting by intra-arterial infusion of 5-[123I] iodo-2'-deoxyuridine in patients with liver metastases from colorectal cancer. G Mariani, S Di Sacco, D Volterrani, L Di Luca, S Buralli, R Di Stefano, ... Journal of nuclear medicine: official publication, Society of Nuclear …, 1996 | 43 | 1996 |
| Reduction of 68Ga-PSMA renal uptake with mannitol infusion: preliminary results F Matteucci, E Mezzenga, P Caroli, V Di Iorio, A Sarnelli, M Celli, L Fantini, ... European journal of nuclear medicine and molecular imaging 44, 2189-2194, 2017 | 35 | 2017 |
| FDG PET/CT response evaluation in malignant pleural mesothelioma patients treated with talc pleurodesis and chemotherapy G Genestreti, A Moretti, S Piciucchi, N Giovannini, R Galassi, E Scarpi, ... Journal of Cancer 3, 241, 2012 | 35 | 2012 |
| PET/CT in multiple myeloma: beyond FDG F Matteucci, G Paganelli, G Martinelli, C Cerchione Frontiers in oncology 10, 622501, 2021 | 33 | 2021 |
| Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer V Conteduca, D Wetterskog, E Scarpi, A Romanel, G Gurioli, A Jayaram, ... British journal of cancer 123 (6), 982-987, 2020 | 32 | 2020 |
| Quantitative accuracy of 177Lu SPECT imaging for molecular radiotherapy E Mezzenga, V D’Errico, M D’Arienzo, L Strigari, K Panagiota, F Matteucci, ... PLoS One 12 (8), e0182888, 2017 | 32 | 2017 |
| Prognostic value of 18F–choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide P Caroli, U De Giorgi, E Scarpi, L Fantini, A Moretti, R Galassi, M Celli, ... European Journal of Nuclear Medicine and Molecular Imaging 45, 348-354, 2018 | 31 | 2018 |
| Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F] Fluoroestradiol … G Bottoni, A Piccardo, F Fiz, G Siri, F Matteucci, A Rocca, O Nanni, ... European Journal of Radiology 141, 109821, 2021 | 29 | 2021 |
| 177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study G Paganelli, M Sansovini, S Nicolini, I Grassi, T Ibrahim, E Amadori, ... European journal of nuclear medicine and molecular imaging 48, 152-160, 2021 | 29 | 2021 |
| Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of 225Ac-PSMA … ML Belli, A Sarnelli, E Mezzenga, F Cesarini, P Caroli, V Di Iorio, L Strigari, ... Frontiers in Oncology 10, 531660, 2020 | 28 | 2020 |
| Incremental diagnostic value of dobutamine stress echocardiography and dobutamine scintigraphy (technetium 99m-labeled sestamibi single-photon emission computed tomography) for … V Di Bello, CR Bellina, E Gori, N Molea, L Talarico, G Boni, E Magagnini, ... Journal of Nuclear Cardiology 3 (3), 212-220, 1996 | 28 | 1996 |
